IDEA #34TQD5 Low-molecular Compounds With Antituberculosis Action

Areas of Application Low-molecular compounds with antituberculosis action Advantages The developed compounds act on the strains of Mycobacterium tuberculosis that are stable to known commercial antituberculosis drugs, in particular, isoniazid, rifampin, and ofl oxacin Specifi cation Chemical names:3-isopropoxybenzaldehyde thiosemicarbazone (1) and N’-[1E)-1-methyl-1H- pyrrol-2-yl)methylene]isonicotinic hydrazide (2). The compounds inhibit the growth of Mycobacterium tuberculosis in aerobic conditions with MIC = 0.79 μM (compound 1) and 0.39 μM (compound 2); the compounds are not cytotoxic with respect to cellular line of human liver HepG2; penetrate through the monolayer of Caco-2 cells, which is in vitro model of the mucous membrane of human small intestine for predicting drug absorption; the binding with proteins of blood plasma makes up 86.8 and 42.1 for compounds 1 and 2, respectively Stage of Development. Suggestion for Commercialization IRL2, TRL2 Seeking partners for preclinical/clinical trials. The ready offering can be proposed to pharmaceutical corporations IPR Protection IPR2